BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
See today's BioWorld
Home
» Post Keytruda royalty sale, Lifearc commits $30M to U.K. antibody firm Kymab
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Post Keytruda royalty sale, Lifearc commits $30M to U.K. antibody firm Kymab
June 25, 2019
By
Nuala Moran
No Comments
LONDON – Fresh from the $1.3 billion sale of its royalty stake in Keytruda (pembrolizumab), the research charity Lifearc is starting to put the money to work, announcing it will invest $30 million in antibody specialist Kymab Group Ltd.
BioWorld